$AWH
Aspira Women's Health Inc.

2024 Q4 Form 10-Q Financial Statement

#000149315224046836 Filed on November 19, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $2.257M
YoY Change 1.8%
Cost Of Revenue $902.0K
YoY Change -0.88%
Gross Profit $1.355M
YoY Change 3.67%
Gross Profit Margin 60.04%
Selling, General & Admin $4.191M
YoY Change -5.29%
% of Gross Profit 309.3%
Research & Development $908.0K
YoY Change -9.02%
% of Gross Profit 67.01%
Depreciation & Amortization $23.00K
YoY Change -42.5%
% of Gross Profit 1.7%
Operating Expenses $5.099M
YoY Change -5.97%
Operating Profit -$3.744M
YoY Change -9.04%
Interest Expense -$5.000K
YoY Change -150.0%
% of Operating Profit
Other Income/Expense, Net $197.0K
YoY Change -67.11%
Pretax Income -$3.547M
YoY Change -24.69%
Income Tax
% Of Pretax Income
Net Earnings -$3.547M
YoY Change -24.63%
Net Earnings / Revenue -157.16%
Basic Earnings Per Share -$0.23
Diluted Earnings Per Share -$0.23
COMMON SHARES
Basic Shares Outstanding 16.67M shares 16.06M
Diluted Shares Outstanding 15.41M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.133M
YoY Change -58.18%
Cash & Equivalents $2.133M
Short-Term Investments
Other Short-Term Assets $291.0K
YoY Change -51.5%
Inventory $290.0K
Prepaid Expenses
Receivables $1.254M
Other Receivables $0.00
Total Short-Term Assets $4.113M
YoY Change -45.68%
LONG-TERM ASSETS
Property, Plant & Equipment $99.00K
YoY Change -55.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $32.00K
YoY Change 146.15%
Total Long-Term Assets $646.0K
YoY Change -40.73%
TOTAL ASSETS
Total Short-Term Assets $4.113M
Total Long-Term Assets $646.0K
Total Assets $4.759M
YoY Change -45.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.551M
YoY Change 84.59%
Accrued Expenses $2.494M
YoY Change -19.26%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due $229.0K
YoY Change -39.42%
Total Short-Term Liabilities $5.466M
YoY Change 5.89%
LONG-TERM LIABILITIES
Long-Term Debt $1.334M
YoY Change 9.61%
Other Long-Term Liabilities $479.0K
YoY Change -83.48%
Total Long-Term Liabilities $1.334M
YoY Change 9.61%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.466M
Total Long-Term Liabilities $1.334M
Total Liabilities $7.279M
YoY Change -21.91%
SHAREHOLDERS EQUITY
Retained Earnings -$530.0M
YoY Change 2.87%
Common Stock $527.5M
YoY Change 4795254.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.520M
YoY Change
Total Liabilities & Shareholders Equity $4.759M
YoY Change -45.06%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$3.547M
YoY Change -24.63%
Depreciation, Depletion And Amortization $23.00K
YoY Change -42.5%
Cash From Operating Activities -$2.920M
YoY Change -187.93%
INVESTING ACTIVITIES
Capital Expenditures $2.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$2.000K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.093M
YoY Change -2.08%
NET CHANGE
Cash From Operating Activities -2.920M
Cash From Investing Activities -2.000K
Cash From Financing Activities 4.093M
Net Change In Cash 1.171M
YoY Change -64.74%
FREE CASH FLOW
Cash From Operating Activities -$2.920M
Capital Expenditures $2.000K
Free Cash Flow -$2.922M
YoY Change -187.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0000926617
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
usd
CY2024Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2024Q1 AWH Warrant Exercise Value
WarrantExerciseValue
usd
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
usd
CY2023Q2 AWH Stock Issued During Periodvalue Reverse Stock Splits
StockIssuedDuringPeriodvalueReverseStockSplits
usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
AWH Financing Expense Related To Equity Line Of Credit Agreement
FinancingExpenseRelatedToEquityLineOfCreditAgreement
usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
usd
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
usd
us-gaap Line Of Credit Facility Decrease Forgiveness1
LineOfCreditFacilityDecreaseForgiveness1
usd
AWH Fair Value Of Warrants Issued In Conjunction With Warrant Inducement Agreement
FairValueOfWarrantsIssuedInConjunctionWithWarrantInducementAgreement
usd
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34810
dei Entity Registrant Name
EntityRegistrantName
Aspira Women’s Health Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0595156
dei Entity Address Address Line1
EntityAddressAddressLine1
12117 Bee Caves Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Building III
dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78738
dei City Area Code
CityAreaCode
(512)
dei Local Phone Number
LocalPhoneNumber
519-0400
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
AWH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16667255 shares
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.001
CY2024Q3 us-gaap Cash
Cash
2133000 usd
CY2023Q4 us-gaap Cash
Cash
2597000 usd
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
15000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1254000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1459000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
436000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
997000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
290000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
227000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
4113000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
5280000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
99000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
165000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
515000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
528000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
258000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
32000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
31000 usd
CY2024Q3 us-gaap Assets
Assets
4759000 usd
CY2023Q4 us-gaap Assets
Assets
6262000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2551000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1261000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2494000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2863000 usd
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
229000 usd
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
166000 usd
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
670000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
192000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
159000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5466000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5119000 usd
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1334000 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1430000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
387000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
427000 usd
CY2024Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
92000 usd
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1651000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
7279000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
8627000 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16284381 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16284381 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10645049 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10645049 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
16000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
11000 usd
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
527473000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
515927000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-530009000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-518303000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-2520000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2365000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4759000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6262000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2257000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2217000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6833000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7024000 usd
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
902000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
910000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2843000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2981000 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
1355000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
1307000 usd
us-gaap Gross Profit
GrossProfit
3990000 usd
us-gaap Gross Profit
GrossProfit
4043000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
908000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
998000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2766000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2958000 usd
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2143000 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1702000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6169000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6069000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2048000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2723000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7902000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9733000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
5099000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
5423000 usd
us-gaap Operating Expenses
OperatingExpenses
16837000 usd
us-gaap Operating Expenses
OperatingExpenses
18760000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3744000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4116000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-12847000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-14717000 usd
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-174000 usd
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1201000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1314000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
233000 usd
CY2024Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-5000 usd
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
12000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-20000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
46000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1000000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
28000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
599000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-153000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
303000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
197000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-590000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1141000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1116000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3547000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4706000 usd
us-gaap Net Income Loss
NetIncomeLoss
-11706000 usd
us-gaap Net Income Loss
NetIncomeLoss
-13601000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.54
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15405672 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15405672 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9776436 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9776436 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13269646 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13269646 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8838342 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8838342 shares
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2365000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-4629000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
400000 usd
CY2024Q1 AWH Stock Issued During Period Value Common Stock Issued Under Direct Offering Net Of Issuance Costs
StockIssuedDuringPeriodValueCommonStockIssuedUnderDirectOfferingNetOfIssuanceCosts
4869000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
362000 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1363000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3530000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
39000 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1101000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
16000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
106000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3709000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3547000 usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
400000 usd
CY2024Q3 AWH Stock Issued During Period Value Common Stock Issued Under Warrant Inducement Agreement Net Of Issuance Costs
StockIssuedDuringPeriodValueCommonStockIssuedUnderWarrantInducementAgreementNetOfIssuanceCosts
1862000 usd
CY2024Q3 AWH Reclassification Of Warrant Liability Upon Exercise
ReclassificationOfWarrantLiabilityUponExercise
245000 usd
CY2024Q3 AWH Stock Issued During Period Value Common Stock Issued Under Private Placement Offering Net Of Issuance Costs
StockIssuedDuringPeriodValueCommonStockIssuedUnderPrivatePlacementOfferingNetOfIssuanceCosts
1838000 usd
CY2024Q3 AWH Stock Issued During Period Value Under Securities Purchase Agreement
StockIssuedDuringPeriodValueUnderSecuritiesPurchaseAgreement
11000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
145000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
235000 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2520000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6979000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6578000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
30000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
396000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
827000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2317000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
38000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
178000 usd
CY2023Q2 AWH Stock Issued During Period Value Common Stock Issued For Entering Into Equity Line Of Credit
StockIssuedDuringPeriodValueCommonStockIssuedForEnteringIntoEquityLineOfCredit
258000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
264000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
224000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-528000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-528000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4706000 usd
CY2023Q3 AWH Stock Issued During Period Value Common Stock Issued Under Direct Offering Net Of Issuance Costs
StockIssuedDuringPeriodValueCommonStockIssuedUnderDirectOfferingNetOfIssuanceCosts
4157000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
421000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-3000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-659000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-659000 usd
us-gaap Net Income Loss
NetIncomeLoss
-11706000 usd
us-gaap Net Income Loss
NetIncomeLoss
-13601000 usd
AWH Noncash Lease Expense Income
NoncashLeaseExpenseIncome
6000 usd
AWH Noncash Lease Expense Income
NoncashLeaseExpenseIncome
-2000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
78000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
162000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
864000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1302000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1314000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
233000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-25000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
3000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1000000 usd
AWH Financing Expense Related To Equity Line Of Credit Agreement
FinancingExpenseRelatedToEquityLineOfCreditAgreement
258000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-205000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
345000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-560000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1011000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
63000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-15000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1290000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
501000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-369000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-313000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-668000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-662000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11092000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12444000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
37000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-37000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12000 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
35000 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
148000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10407000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4255000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-722000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8201000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2855000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13557000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2133000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5356000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2133000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5100000 usd
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
256000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2133000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5356000 usd
us-gaap Interest Paid Net
InterestPaidNet
43000 usd
us-gaap Interest Paid Net
InterestPaidNet
41000 usd
us-gaap Line Of Credit Facility Decrease Forgiveness1
LineOfCreditFacilityDecreaseForgiveness1
1000000 usd
AWH Fair Value Of Warrants Issued In Conjunction With Warrant Inducement Agreement
FairValueOfWarrantsIssuedInConjunctionWithWarrantInducementAgreement
1323000 usd
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
258000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
169000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
318000 usd
us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_847_eus-gaap--NatureOfOperations_zs4uKGswvYP2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zuxXAwij6IS9">Organization</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aspira Women’s Health Inc. (“Aspira” and its wholly-owned subsidiaries are collectively referred to as the “Company”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company currently markets and sells the following products and related services:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) the Ova1Plus workflow, which uses Ova1 as the primary test and Overa as a reflex for Ova1 intermediate range results. Ova1 is a qualitative serum test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician’s independent clinical and radiological evaluation does not indicate malignancy. Overa is a second-generation biomarker test intended to maintain Ova1’s high sensitivity while improving specificity. The Ova1 workflow leverages the strengths of Ova1’s (MIA) sensitivity and Overa’s (MIAG2G) specificity to reduce incorrectly elevated results; and</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) OvaWatch, a Laboratory Developed Test (“LDT”) intended in the initial and periodic clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collectively, these tests are referred to and marketed as OvaSuite.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the nine months ended September 30, 2024 and 2023, the Company’s product and related revenue was limited to the products described above, as well as residual revenue from Aspira GenetiX, which was discontinued in the third quarter of 2022. The Company’s products are distributed through its own national sales force, including field sales, inside sales and a contracted sales team, through its proprietary decentralized testing platform and cloud service marketed as Aspira Synergy, and through marketing and distribution agreements with BioReference Health, LLC and ARUP Laboratories<span style="background-color: white">.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overa is currently not offered commercially except as a reflex test performed as part of the Ova1Plus workflow.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-530009000 usd
CY2024Q3 AWH Working Capital Deficit
WorkingCapitalDeficit
1353000 usd
us-gaap Net Income Loss
NetIncomeLoss
-11706000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11092000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2133000 usd
CY2024Q3 AWH Market Capitalisation
MarketCapitalisation
35000000 usd
CY2024Q3 AWH Adjustments To Estimates Of Variable Consideration To Derecognize Revenue
AdjustmentsToEstimatesOfVariableConsiderationToDerecognizeRevenue
11000 usd
AWH Adjustments To Estimates Of Variable Consideration To Derecognize Revenue
AdjustmentsToEstimatesOfVariableConsiderationToDerecognizeRevenue
17000 usd
CY2024Q3 AWH Impairment Losses On Accounts Receivable
ImpairmentLossesOnAccountsReceivable
0 usd
AWH Impairment Losses On Accounts Receivable
ImpairmentLossesOnAccountsReceivable
0 usd
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
68000 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
684000 usd
CY2024Q3 AWH Software Licenses
SoftwareLicenses
45000 usd
CY2023Q4 AWH Software Licenses
SoftwareLicenses
103000 usd
CY2024Q3 AWH Prepaid Subscriptions
PrepaidSubscriptions
32000 usd
CY2023Q4 AWH Prepaid Subscriptions
PrepaidSubscriptions
26000 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
291000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
184000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
436000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
997000 usd
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
1563000 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
1596000 usd
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
229000 usd
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
166000 usd
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1334000 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1430000 usd
CY2024Q3 us-gaap Contractual Obligation
ContractualObligation
1569000 usd
CY2024Q3 us-gaap Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
58000 usd
CY2024Q3 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
233000 usd
CY2024Q3 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
238000 usd
CY2024Q3 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
145000 usd
CY2024Q3 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
213000 usd
CY2024Q3 AWH Contractual Obligation Due After Fourth Year
ContractualObligationDueAfterFourthYear
682000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
54000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
229000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
223000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
84000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
52000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
642000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
63000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
579000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
192000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
387000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
257000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
334000 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y9M18D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0725 pure
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0808 pure
CY2024Q3 us-gaap Royalty Expense
RoyaltyExpense
71000 usd
CY2023Q3 us-gaap Royalty Expense
RoyaltyExpense
75000 usd
us-gaap Royalty Expense
RoyaltyExpense
222000 usd
us-gaap Royalty Expense
RoyaltyExpense
253000 usd
CY2024Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1509000 usd
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1189000 usd
CY2024Q3 AWH Collaboration And Research Agreements Expenses
CollaborationAndResearchAgreementsExpenses
128000 usd
CY2023Q4 AWH Collaboration And Research Agreements Expenses
CollaborationAndResearchAgreementsExpenses
217000 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
371000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
951000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
486000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
506000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2494000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2863000 usd
CY2024Q3 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
1862000 usd
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4475068 shares
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
799985 shares
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
379000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
418000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
863000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1302000 usd
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
379000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
418000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
863000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1302000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3547000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4706000 usd
us-gaap Net Income Loss
NetIncomeLoss
-11706000 usd
us-gaap Net Income Loss
NetIncomeLoss
-13601000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15405672 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15405672 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9776436 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9776436 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13269646 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13269646 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8838342 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8838342 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.54
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001493152-24-046836-index-headers.html Edgar Link pending
0001493152-24-046836-index.html Edgar Link pending
0001493152-24-046836.txt Edgar Link pending
0001493152-24-046836-xbrl.zip Edgar Link pending
awh-20240930.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
awh-20240930_def.xml Edgar Link unprocessable
awh-20240930_lab.xml Edgar Link unprocessable
awh-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
awh-20240930_cal.xml Edgar Link unprocessable